

Malawi

Support for Vaccine: Inactivated Polio Virus
This Decision Letter sets out the Programme Terms of a Programme.

1. Country:	Malawi																		
2. Vaccine grant number:	1518-MWI-25c-X, 18-MWI-08P-Y, 19-MWI-25b-X																		
3. Date of Decision Letter:	10 September 2019																		
4. Date of the Partnership Framework Agreement:	29 October 2013																		
5. Programme title:	New Vaccine Support (NVS), Inactivated Polio Virus, Routine																		
6. Vaccine type:	Inactivated Polio Virus																		
7. Requested product presentation and formulation of vaccine:	Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID																		
8. Programme Duration:¹	2015-2019																		
9. Programme Budget (indicative):²	(subject to the terms of the Partnership Framework Agreement, if applicable)																		
	2015-2018	2019	2020	2021	2022	2023	Total ²												
Programme Budget (US\$)	669,464	2,007,500	-	-	-	-	2,676,964												
10. Vaccine introduction grant	<table border="1"> <thead> <tr> <th colspan="3">Approval</th> </tr> <tr> <th>Year</th> <th>Grant Number</th> <th>Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td>2018</td> <td>18-MWI-08P-Y</td> <td>372,885</td> </tr> <tr> <td>2015</td> <td>15-MWI-08h-Y</td> <td>442,750</td> </tr> </tbody> </table>							Approval			Year	Grant Number	Amount (US\$)	2018	18-MWI-08P-Y	372,885	2015	15-MWI-08h-Y	442,750
Approval																			
Year	Grant Number	Amount (US\$)																	
2018	18-MWI-08P-Y	372,885																	
2015	15-MWI-08h-Y	442,750																	
11. Product switch grant	Not applicable																		
12. Indicative Annual Amounts:³	(subject to the terms of the Partnership Framework Agreement, if applicable)																		
Type of supplies to be purchased with Gavi funds	2015-2018	2019																	
Number of vaccine doses		672,200																	
Annual Amounts (US\$)	669,464	2,007,500																	

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

13. Procurement agency:	UNICEF. The Country shall release its co-financing payments each year to UNICEF.						
14. Self-procurement:	Not applicable						
15. Co-financing obligations:	Gavi's usual co-financing requirements do not apply to IPV. However, the Country is encouraged to contribute to vaccine and/or supply costs for IPV.						
16. Operational support for catch-up campaigns:	Not applicable						
17. Additional Reporting Requirements:	<table border="1"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. </td> <td>31 March 15 May</td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Gavi Secretariat</td> </tr> </tbody> </table>		Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 15 May	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat
	Due dates						
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 15 May						
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat						
18. Financial clarifications:	Not applicable						
19. Other conditions:	<p>Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.</p> <p>If Malawi envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Malawi.</p>						

Signed by,

On behalf of Gavi



Thabani Maphosa,
Managing Director, Country Programmes
10 September 2019